Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the long-term effectiveness of Mavenclad®
tablets, in terms of disease activity and safety, in participants with highly-active
relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial
MS700568_0022 (NCT03364036).
Phase:
Phase 4
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany